# Effects of Semaglutide in HIV-Associated Lipohypertrophy

> **NCT04019197** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Case Western Reserve University** · enrollment: 108 (actual)

## Conditions studied

- HIV/AIDS
- Lipohypertrophy
- Obesity

## Interventions

- **DRUG:** Semaglutide Injectable Product
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04019197
- **Lead sponsor:** Case Western Reserve University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-05-16
- **Primary completion:** 2024-04-30
- **Final completion:** 2026-09-01
- **Target enrollment:** 108 (ACTUAL)
- **Last updated:** 2026-05-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04019197

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04019197, "Effects of Semaglutide in HIV-Associated Lipohypertrophy". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04019197. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*